Center for Clinical Effectiveness, Baylor Scott & White Health, Dallas, Texas.
Robbins Institute for Health Policy and Leadership, Baylor University, Waco, Texas.
JAMA Surg. 2018 Aug 1;153(8):757-763. doi: 10.1001/jamasurg.2018.1039.
Opioids are commonly used for pain control during and after invasive procedures. However, opioid-related adverse drug events (ORADEs) are common and have been associated with worse patient outcomes.
To examine the incidence of ORADEs in patients undergoing hospital-based surgical and endoscopic procedures and to evaluate the association of ORADEs with clinical and cost outcomes.
DESIGN, SETTING, AND PARTICIPANTS: In this retrospective study of clinical and administrative data, ORADEs were identified using International Classification of Diseases, Ninth Revision diagnosis codes for known adverse effects of opioids or by opioid antagonist use. Multivariable regression analysis was used to measure the association of ORADEs with outcomes after adjusting for potential confounding factors. The setting was 21 acute care hospitals in a large integrated health care delivery system. Participants were 135 379 patients (aged ≥18 years, admitted from January 1, 2013, to September 30, 2015) who underwent surgical and endoscopic procedures and were given opioids.
Opioid use, reported as morphine milligram equivalent doses.
Opioid-related adverse drug events and their association with inpatient mortality, discharge to another care facility, length of stay, cost of hospitalization, and 30-day readmission.
Among 135 379 adult patients in this study (67.5% female), 14 386 (10.6%) experienced at least one ORADE. Patients with ORADEs were more likely to be older, of white race/ethnicity, and male and have more comorbidities. Patients with ORADEs received a higher total dose of opioids (median morphine milligram equivalent dose, 46.8 vs 30.0 mg; P < .001) and for a longer duration (median, 3.0 vs 2.0 days; P < .001). In adjusted analyses, ORADEs were associated with increased inpatient mortality (odds ratio [OR], 28.8; 95% CI, 24.0-34.5), greater likelihood of discharge to another care facility (OR, 2.9; 95% CI, 2.7-3.0), prolonged length of stay (OR, 3.1; 95% CI, 2.8-3.4), high cost of hospitalization (OR, 2.7; 95% CI, 2.4-3.0), and higher rate of 30-day readmission (OR, 1.3; 95% CI, 1.2-1.4). ORADEs were associated with a 2.9% increase in absolute mortality, an $8225 increase in cost for the index hospitalization, and a 1.6-day increase in length of stay for the index hospitalization.
Opioid-related adverse drug events were common among patients undergoing hospital-based invasive procedures and were associated with significantly worse clinical and cost outcomes. Hospital-acquired harm from ORADEs in the surgical patient population is an important opportunity for health systems to improve patient safety and reduce cost.
阿片类药物常用于控制侵入性手术期间和之后的疼痛。然而,阿片类药物相关的不良药物事件(ORADEs)很常见,并且与更差的患者预后有关。
检查在接受医院手术和内镜检查的患者中 ORADEs 的发生率,并评估 ORADEs 与临床和成本结果的关联。
设计、地点和参与者:在这项使用国际疾病分类、第九版诊断代码识别已知阿片类药物不良反应或使用阿片类药物拮抗剂的回顾性研究中,确定了 ORADEs。多变量回归分析用于在调整潜在混杂因素后测量 ORADEs 与结果之间的关联。该研究地点是一个大型综合医疗服务系统中的 21 家急性护理医院。参与者为 135379 名(年龄≥18 岁,2013 年 1 月 1 日至 2015 年 9 月 30 日入院)接受手术和内镜检查并使用阿片类药物的患者。
阿片类药物使用,报告为吗啡毫克当量剂量。
阿片类药物相关的不良药物事件及其与住院死亡率、转至其他护理机构、住院时间、住院费用和 30 天再入院的关系。
在这项研究中的 135379 名成年患者中(67.5%为女性),有 14386 名(10.6%)经历了至少一次 ORADE。发生 ORADE 的患者年龄更大、为白种人/西班牙裔,且更可能为男性,并伴有更多的合并症。发生 ORADE 的患者接受了更高剂量的阿片类药物(中位数吗啡毫克当量剂量为 46.8 毫克与 30.0 毫克;P<0.001)和更长的用药时间(中位数 3.0 天与 2.0 天;P<0.001)。在调整后的分析中,ORADEs 与住院死亡率增加(优势比[OR],28.8;95%CI,24.0-34.5)、更有可能转至其他护理机构(OR,2.9;95%CI,2.7-3.0)、住院时间延长(OR,3.1;95%CI,2.8-3.4)、住院费用增加(OR,2.7;95%CI,2.4-3.0)和 30 天再入院率增加(OR,1.3;95%CI,1.2-1.4)相关。ORADEs 导致绝对死亡率增加 2.9%,索引住院费用增加 8225 美元,索引住院时间增加 1.6 天。
阿片类药物相关的不良药物事件在接受医院侵入性手术的患者中很常见,并且与明显更差的临床和成本结果相关。外科患者人群中 ORADEs 引起的医院获得性伤害是改善患者安全和降低成本的重要机会。